Hale Animal Health is developing a range of novel veterinary pharmaceuticals for companion animals, self-described as working to elevate the quality of life for every pet by offering new and improved solutions for treatment.

Hale Animal Health

Hale Animal Health | 181 followers on LinkedIn. We exist to elevate the quality of life of every pet. | Hale develop novel veterinary pharmaceuticals with a focus on providing new and improved solutions to veterinary medicine, products that are effective and without unwanted side effects.

Chief Executive Officer - Hale Animal Health

Leila de Koster

Director of Research and Development - Hale Animal Health

Keryn Davies

Hale is very excited to welcome David Gill on board as Science Advisory Partner. David has over 45 years experience as a pharmaceutical scientist working on drug development for big pharma through to smaller specialist companies. David was previously the CSO at Argenta and more recently the CSO at a medicinal cannabis company. David’s extensive experience in animal health therapeutics coupled with his cannabis knowledge is a huge asset to Hale and we are delighted to have him involved. #animalhealth #veterinarymedicine #CBD #cannabis

Hale is thrilled to have appointed Dr. Thomas Overbay as an advisor to the business. Tom has over 36 years of experience in the veterinary pharmaceutical industry, working with major animal health companies right through to start ups. Tom’s input in to our product development and business strategies will be invaluable, particularly as we navigate our way towards FDA approval and launch in to the US market. Great to be working with you, Tom! #animalhealth #veterinarymedicine #cannabis #CBD

THE RESULTS ARE IN! Hale is proud to announce the results of our recent clinical trial, a double blinded controlled study, treating pain in dogs suffering from osteoarthritis with our novel, cannabis derived, product formulation; 🔹 The Hale product treated pain just as well as the control, a market leading non-steroidal anti-inflammatory 🔹 We saw a 93% success rate with our treatment group, the accepted norm is around a 50 - 60% success rate 🔹 To be deemed efficacious, we needed to see a drop of at least 2 points on the dog’s Clinical Sum Score (their pain score, given by the vet). Some of the dogs in the Hale treatment group were dropping by 7, 8 and even 9 points! 🔹 Feedback from owners was very positive, with many commenting that their dogs were acting like puppies again Pictured here is Kruiz who was in the Hale treatment group and started the trial with a pain score of 10. Kruiz finished the trial with a score of 1, a whopping 9 point drop. Kruiz’s owner shared this feedback with us; “At the park he was like a puppy again, trotting around, sniffing, excited, happy… haven’t seen Kruiz like this for a very long time.” #cannabis #CBD #veterinarymedicine #animalhealth

We’re thrilled to welcome Keryn Davies to the team as Director of Research and Development. Keryn brings two decades of experience in pharmaceutical product development, with a unique blend of skills in project management and analytical chemistry coupled with expertise working with cannabis. Welcome to the team, Keryn! 🎉

The BIOTech New Zealand Life Sciences Summit was the perfect environment to have this panel discussion on the topic of future proofing Aotearoa's animal health innovation system. Our CEO Leila de Koster was in great company alongside Kjesten Wiig , Shirli Notcovich , Thomas Overbay and Duncan Mackintosh , discussing the challenges, strengths and opportunities we have here in Aotearoa New Zealand. #veterinarymedicine #animalhealth #biotech

Metric
Company Name	Hale Animal Health
Symbol
MSH ID	NZ:CO:HALEANIMAL
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Animal Health
Country	NZ
Stage
Employee Count
Website	haleanimal.co.nz
LinkedIn	haleanimal
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CO

NZ:CO:HALEANIMAL

Hale Animal Health

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue